The content on this site is intended for healthcare professionals only
Prof Schöffski answers "yes" to the question "Have additional treatment options had a tangible impact on the first-line treatment of mRCC?" and tells us why.
He draws examples from the COMPARZ which showed that pazopanib had better scores than sunitinib for a number of clinically relevant domains and was preferred by patients.
GlaxoSmithKline fully provided for the costs of this symposium, honoraria for the chairs & speakers and provided input into the symposium agenda/content.
ESMO 2024: Optimising the personalisation of prostate cancer treatment
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
Choosing Wisely in radiology Tanzania
Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours
Digital rectal examination is not useful as a solitary screening tool for prostate cancer in young men
Plasma miR371 detects MRD and early relapse of germ cell tumours
Cabozantinib after checkpoint inhibitors demonstrates preliminary efficacy in advanced RCC
Hypofractionated high dose intensity modulated radiotherapy non-inferior for prostate cancer
